Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas H Bugge

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
The Journal of Biological Chemistry|August 21, 2008
Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activityRoman Szabo, John P Hobson, Karin List, et al.
Experimental Cell Research|January 20, 2004
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IVLars Kjøller, Lars H Engelholm, Maria Høyer-Hansen, et al.
Thrombosis and Haemostasis|July 31, 2003
Type II transmembrane serine proteasesRoman Szabo, Qingyu Wu, Robert B Dickson, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2011
Role for the actomyosin complex in regulated exocytosis revealed by intravital microscopyAndrius Masedunskas, Monika Sramkova, Laura Parente, et al.
Molecular Cancer Therapeutics|January 25, 2006
Antitumor efficacy of a urokinase activation-dependent anthrax toxinBirgitte Rønø, John Rømer, Shihui Liu, et al.
The Journal of Biological Chemistry|June 26, 2014
The protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasinStine Friis, Katiuchia Uzzun Sales, Jeffrey Martin Schafer, et al.
The Journal of Clinical Investigation|November 18, 2003
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related proteinManuel Yepes, Maria Sandkvist, Elizabeth G Moore, et al.
Nature Biotechnology|May 17, 2005
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxinShihui Liu, Vivien Redeye, Jeffrey G Kuremsky, et al.
Molecular Cancer Therapeutics|October 17, 2006
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell typesRalph J Abi-Habib, Ravibhushan Singh, Shihui Liu, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
The Journal of Biological Chemistry|August 21, 2008
Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activityRoman Szabo, John P Hobson, Karin List, et al.
Experimental Cell Research|January 20, 2004
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IVLars Kjøller, Lars H Engelholm, Maria Høyer-Hansen, et al.
Thrombosis and Haemostasis|July 31, 2003
Type II transmembrane serine proteasesRoman Szabo, Qingyu Wu, Robert B Dickson, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2011
Role for the actomyosin complex in regulated exocytosis revealed by intravital microscopyAndrius Masedunskas, Monika Sramkova, Laura Parente, et al.
Molecular Cancer Therapeutics|January 25, 2006
Antitumor efficacy of a urokinase activation-dependent anthrax toxinBirgitte Rønø, John Rømer, Shihui Liu, et al.
The Journal of Biological Chemistry|June 26, 2014
The protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasinStine Friis, Katiuchia Uzzun Sales, Jeffrey Martin Schafer, et al.
The Journal of Clinical Investigation|November 18, 2003
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related proteinManuel Yepes, Maria Sandkvist, Elizabeth G Moore, et al.
Nature Biotechnology|May 17, 2005
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxinShihui Liu, Vivien Redeye, Jeffrey G Kuremsky, et al.
Molecular Cancer Therapeutics|October 17, 2006
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell typesRalph J Abi-Habib, Ravibhushan Singh, Shihui Liu, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Pageof 14